Want to see APGE full AI Analyst Report?
APGE Stock Chart & Stats
$134.85
$0.02(0.01%)
At close: 4:00 PM EDT
$134.85
$0.02(0.01%)
Day’s Range― - ―
52-Week Range$35.39 - $135.09
Previous CloseN/A
Volume558.23K
Average Volume (3M)1.19M
Market Cap
$10.22B
Enterprise Value$9.15K
Total Cash (Recent Filing)$971.93M
Total Debt (Recent Filing)$6.83M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 16, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding62,201,090
10 Day Avg. Volume1,162,107
30 Day Avg. Volume1,189,482
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$131.18Price Target Upside-2.72% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-4.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetMinimal leverage and a sizable capital base provide flexibility to fund clinical development, absorb setbacks, and pursue strategic opportunities without immediate dependence on equity financing.
Positive Phase 2 EfficacyStrong Phase 2 efficacy supports advancement into Phase 3 and improves the commercial potential of the lead asset, while expansion into asthma and eosinophilic esophagitis broadens future opportunities.
Non-dilutive FinancingAccess to substantial royalty financing and potential debt can fund late-stage trials and commercialization while reducing near-term equity dilution risk and extending strategic financial flexibility.
Bears Say
Pre-commercial Revenue ProfileThe company has not established a meaningful revenue stream or operating leverage, leaving its long-term economics dependent on successful clinical development, regulatory approval, and eventual product launches.
Large And Rising Cash BurnHeavy cash consumption raises ongoing funding and execution demands. Even with current resources and financing options, delays or weaker results could increase the need for additional capital.
Clinical And Transaction Execution RiskValue depends on successful Phase 3 development and completion of the acquisition. Clinical setbacks, regulatory hurdles, or integration and leadership changes could reduce expected strategic benefits.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics’s price range in the past 12 months?
Apogee Therapeutics lowest stock price was $35.39 and its highest was $135.09 in the past 12 months.
What is Apogee Therapeutics’s market cap?
Apogee Therapeutics’s market cap is $10.22B.
When is Apogee Therapeutics’s upcoming earnings report date?
Apogee Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 74 days.
How were Apogee Therapeutics’s earnings last quarter?
Apogee Therapeutics released its earnings results on Aug 10, 2026. The company reported -$1.14 earnings per share for the quarter, missing the consensus estimate of -$1.072 by -$0.068.
Is Apogee Therapeutics overvalued?
According to Wall Street analysts Apogee Therapeutics’s price is currently Overvalued.
Does Apogee Therapeutics pay dividends?
Apogee Therapeutics does not currently pay dividends.
What is Apogee Therapeutics’s EPS estimate?
Apogee Therapeutics’s EPS estimate is -1.15.
How many shares outstanding does Apogee Therapeutics have?
Apogee Therapeutics has 62,201,090 shares outstanding.
What happened to Apogee Therapeutics’s price movement after its last earnings report?
Apogee Therapeutics reported an EPS of -$1.14 in its last earnings report, missing expectations of -$1.072. Following the earnings report the stock price went down -0.141%.
Which hedge fund is a major shareholder of Apogee Therapeutics?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$131.18 (-2.72% Downside)
$131.18 (-2.72% Downside)
Blogger Sentiment
Neutral
APGE Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
256.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
103.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apogee Therapeutics
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$131.18
▼(-2.72% Downside)
Technical Analysis
Ownership Overview
5.56% Insiders
39.36% Mutual Funds
7.48% Other Institutional Investors
33.87% Public Companies and
Individual Investors